{"filing":{"accession_number":"0001104659-26-095460","cik":"0001279704","ticker":"CLRB","company_name":"Cellectar Biosciences, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"tm2623056d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/tm2623056d1_8k.htm"},"events":[{"id":27495,"run_id":25065,"accession_number":"0001104659-26-095460","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The filing includes condensed consolidated balance sheets, statements of operations with net loss of $6.9 million for the quarter, and per-share metrics. The press release was issued on August 13, 2026, and furnished as Exhibit 99.1, which is the typical format for Item 2.02 earnings disclosures. While the release also includes corporate updates on clinical trial progress, the primary disclosure is the financial results for the period.","company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29063,"accession_number":"0001104659-26-095460","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The filing includes condensed consolidated balance sheets, statements of operations with net loss of $6.9 million for the quarter, and per-share metrics. The press release was issued on August 13, 2026, and furnished as Exhibit 99.1, which is the typical format for Item 2.02 earnings disclosures. While the release also includes corporate updates on clinical trial progress, the primary disclosure is the financial results for the period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:26:47.292241+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29063,"accession_number":"0001104659-26-095460","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026). The filing includes condensed consolidated balance sheets, statements of operations with net loss of $6.9 million for the quarter, and per-share metrics. The press release was issued on August 13, 2026, and furnished as Exhibit 99.1, which is the typical format for Item 2.02 earnings disclosures. While the release also includes corporate updates on clinical trial progress, the primary disclosure is the financial results for the period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T11:26:47.292241+00:00","company_name":"Cellectar Biosciences, Inc.","ticker":"CLRB","filing_date":"2026-08-13"}]}